This highly visible leadership role is expected to partner closely with Process Development, Quality Control, Quality Assurance, Regulatory CMC, Pharmaceutical Development, Translational Sciences, Program Teams, and external CRO/CDMO partners to ensure that bioassay strategies support clinical development, regulatory submissions, commercial readiness, and product lifecycle management. Drive development of robust, mechanism-of-action-based potency and plate-based impurity methods for complex biologics, including enzymatic activity, receptor binding, cellular uptake, signaling, functional cell-based assays, reporter assays, and other relevant biological readouts.